Advertisement
YOU ARE HERE: LAT HomeCollectionsVicuron Pharmaceuticals Inc
IN THE NEWS

Vicuron Pharmaceuticals Inc

FEATURED ARTICLES
BUSINESS
June 17, 2005 | From Reuters
Pfizer Inc. on Thursday said that it planned to buy Vicuron Pharmaceuticals Inc., a biotechnology company with two promising infection treatments that could soon receive regulatory approval, for $1.9 billion in cash. Pfizer hopes the acquisition will help it offset lost sales from its anti-fungal treatment Diflucan, which recently lost patent protection, and an expected slide in sales of its antibiotic Zithromax, which could face generic competition later this year.
ARTICLES BY DATE
BUSINESS
June 17, 2005 | From Reuters
Pfizer Inc. on Thursday said that it planned to buy Vicuron Pharmaceuticals Inc., a biotechnology company with two promising infection treatments that could soon receive regulatory approval, for $1.9 billion in cash. Pfizer hopes the acquisition will help it offset lost sales from its anti-fungal treatment Diflucan, which recently lost patent protection, and an expected slide in sales of its antibiotic Zithromax, which could face generic competition later this year.
Advertisement
BUSINESS
October 20, 2006 | From the Associated Press
Four pharmaceutical companies reported higher third-quarter earnings and sales Thursday, but Pfizer Inc., the world's largest drug maker, predicted flat sales growth and more cost cutting ahead. Pfizer said the challenging operating environment was pushing it to slash costs beyond a program announced last year designed to cut $4 billion in expenses by 2008. Specifics are set to be announced in January. Jeffrey B.
BUSINESS
June 23, 2005 | Denise Gellene, Times Staff Writer
Faced with patent expirations on highly profitable drugs, big pharmaceutical firms are turning to small biotechs to restock their medicine chests. The latest example came last week, when Pfizer Inc. agreed to buy Vicuron Pharmaceuticals Inc. for $1.9 billion. Vicuron, based in King of Prussia, Pa., worked on antibiotics and drugs for fungal infections, key areas for Pfizer. The acquisition followed one in April by GlaxoSmithKline, which agreed to buy Corixa Corp.
Los Angeles Times Articles
|